The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial

Mostafa Najafipour ¹ , Farzad Najafipour ² * , Alireza Ostadrahimi ³, Maryam Ghavami ¹, Zohreh Razaghi ², Helda Tutunchi ², Naimeh Mesri Alamdari ² *

Cited by CrossRef:

1- Mesri Alamdari N, Barghaman M, Roshanravan N, Mobasseri M, Tutunchi H, Baharami A, Aliasgarzadeh A, Sadra V. Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial. BMC Res Notes. 2025;18(1) [Crossref]

2- Abdel‐Rahman S, Al‐Shiab R, Shah E, Güldan M, Ak A, Yilmaz Z, Fidan D, Ozbek L, Kanbay M. Efficacy and safety of GLP‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis. Diabetes Obesity Metabolism. 2026; [Crossref]